Archive for Bile Duct Cancer (Cholangiocarcinoma)

“A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also knownas MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA)Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer”

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRĪ± overexpressing tumors

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours